Parkinson's disease

  title={Parkinson's disease},
  author={Andrew John Lees and John Hardy and Tam{\'a}s R{\'e}v{\'e}sz},
  journal={The Lancet},
Often overlooked neuropsychiatric syndromes in Parkinson's disease
The main features and pathology of PD will be briefly outlined followed by a review of the epidemiology, aetiology, clinical features, and treatment of other often overlooked neuropsychiatric syndromes associated with PD.
Alpha-synuclein in the neurodegenerative mechanisms of Parkinson's disease and dementia with Lewy bodies
A sound hypothesis for the role of alpha-synuclein in the pathogenesis of PD and DLB has been proposed and validates past studies, which have detailed a role in both neuroprotection through chaperone activity, and in neurotoxicity through a toxic gain of function mechanism.
Medical management of Parkinson's disease.
  • M. Goldenberg
  • Medicine, Biology
    P & T : a peer-reviewed journal for formulary management
  • 2008
The availability of effective pharmacological treatment has radically altered the prognosis of PD; in most cases, good functional mobility can be maintained for many years, and the life expectancy of adequately treated patients is increased substantially.
Biomarkers of Parkinson's disease: present and future.
Recent advances in Parkinson’s disease genetics
Pathways involved in mitochondrial quality control, lysosomal function and immune function are emerging as important in the pathogenesis of PD and these pathways represent a target for therapeutic intervention and a way in which the heterogeneity of disease cause, as well as disease mechanism, can be established.
The human olfactory system in two proteinopathies: Alzheimer’s and Parkinson’s diseases
Connectomic approaches reveal a number of hubs in the olfactory system that are key interconnectors with the main hubs of network dysfunction in Alzheimer's and Parkinson's diseases, and why some neuronal populations are vulnerable while others are resistant to pathology and to what extent glia prevent and/or facilitate proteinopathy spreading.
Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine
The development of more reliable biomarkers at asymptomatic stages of the disease, and the use of genetic profiling of patients will surely permit a more effective treatment of PD.
1 Update in Parkinson ’ s Disease
This monograph is designed to make a comprehensive review of all aspects of both clinical as pathophysiological and therapeutic concerning PD, as well as an update on the innovative aspects of the disease primarily focused on identifying new genetic factors and new outlook therapeutics.
Analysis of a murine Pink1 deficiency in serotonergic and dopaminergic neurons in respect of Parkinson´s disease
The serotonergic and dopaminergic system potentially plays a role in the development of PD-related non-motor symptoms upon Pink1 deficiency, as well as uncovering possible compensatory mechanisms.